How a Merck cancer breakthrough caused Bristol-Myers’ stock to plunge
Rival drugmakers Bristol-Myers Squibb Co. and Merck & Co., which are both developing a treatment for the same type of lung cancer, have been playing a game of stock market seesaw.
Never was that more true than Monday, when Merck’s MRK, +1.80% positive clinical trial data lifted it a mere 1.6%, while Bristol’s BMY, -0.14% bad news — made worse in contrast with Merck’s — sent it shuddering down 10.6%.
Merck announced two positive clinical trial results on Sunday, both for its Keytruda treatment on metastatic non-small cell lung cancer, and published the results in respected journals on Monday.
http://www.marketwatch.com/story/ho...used-bristol-myers-stock-to-plunge-2016-10-10
cheers
- Forums
- ASX - By Stock
- VLA
- How Merck Caused Bristol-Myers' Plunge
How Merck Caused Bristol-Myers' Plunge
-
- There are more pages in this discussion • 15 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add VLA (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
I88
INFINI RESOURCES LIMITED
Charles Armstrong, CEO
Charles Armstrong
CEO
SPONSORED BY The Market Online